Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab PK/PD in Asian and Caucasian Healthy Volunteers
NCT03859219Phase 1Completed
- Sponsor
- UCB
- Start
- Mar 2019
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rozanolixizumab in myasthenia gravis (MG) (11 arms), sponsored by UCB. Primary endpoints: Treatment-emergent adverse events, Maximum observed plasma concentration up to 216 hours and 2 more. Started Mar 2019; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03859219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03859219.